May 30, 2018 06:52 AM EDT

FDA executes a 180 on TherapeuticsMD therapy, handing it an OK — and stoking concerns about political influence

John Carroll

Editor & Founder

A year after the FDA handed TherapeuticsMD $TXMD a rejection letter for its therapy preventing vaginal pain during sex, the agency has done a complete …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA executes a 180 on TherapeuticsMD therapy, handing it an OK — and stoking concerns about political influence

John Carroll

Editor & Founder

Sign up to read this article for free.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Advocacy groups and experts call for decade-long ban on germline editing

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

CRISPR patent spat revived by federal appeals court ruling

Some generics, biosimilar drugmakers say they can withstand tariff impact

FDA ex­e­cutes a 180 on Ther­a­peu­tic­sMD ther­a­py, hand­ing it an OK — and stok­ing con­cerns about po­lit­i­cal in­flu­ence

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

FDA executes a 180 on TherapeuticsMD therapy, handing it an OK — and stoking concerns about political influence

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Advocacy groups and experts call for decade-long ban on germline editing

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

CRISPR patent spat revived by federal appeals court ruling

Some generics, biosimilar drugmakers say they can withstand tariff impact